HC Wainwright reiterated their buy rating on shares of CG Oncology (NASDAQ:CGON - Free Report) in a research report released on Friday,Benzinga reports. HC Wainwright currently has a $75.00 price target on the stock.
Several other brokerages have also issued reports on CGON. UBS Group initiated coverage on CG Oncology in a research note on Thursday, October 24th. They set a "buy" rating and a $60.00 price target for the company. Royal Bank of Canada began coverage on shares of CG Oncology in a research report on Monday, September 23rd. They set an "outperform" rating and a $66.00 price target on the stock. Roth Capital upgraded shares of CG Oncology to a "strong-buy" rating in a report on Tuesday, August 27th. Roth Mkm initiated coverage on shares of CG Oncology in a report on Tuesday, August 27th. They set a "buy" rating and a $65.00 target price on the stock. Finally, Bank of America reissued a "buy" rating and issued a $65.00 price target on shares of CG Oncology in a research note on Tuesday, October 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, CG Oncology has a consensus rating of "Buy" and an average target price of $63.88.
View Our Latest Stock Report on CG Oncology
CG Oncology Price Performance
NASDAQ CGON traded up $1.03 during trading on Friday, reaching $34.59. The company's stock had a trading volume of 661,828 shares, compared to its average volume of 475,634. The firm has a fifty day moving average of $35.78 and a 200 day moving average of $34.88. CG Oncology has a one year low of $25.77 and a one year high of $50.23.
CG Oncology (NASDAQ:CGON - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.30 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. As a group, equities analysts anticipate that CG Oncology will post -1.31 EPS for the current fiscal year.
Insiders Place Their Bets
In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $34.54, for a total value of $34,540.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Hedge Funds Weigh In On CG Oncology
A number of hedge funds and other institutional investors have recently made changes to their positions in CGON. State Street Corp increased its position in CG Oncology by 73.0% during the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company's stock valued at $64,166,000 after purchasing an additional 717,722 shares during the period. Yu Fan bought a new stake in shares of CG Oncology during the 2nd quarter valued at about $49,828,000. Janus Henderson Group PLC increased its position in shares of CG Oncology by 7.0% during the third quarter. Janus Henderson Group PLC now owns 1,526,534 shares of the company's stock valued at $57,596,000 after buying an additional 99,517 shares during the period. Franklin Resources Inc. raised its stake in CG Oncology by 8.9% in the third quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company's stock worth $46,157,000 after buying an additional 100,106 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in CG Oncology by 96.2% in the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock worth $40,701,000 after buying an additional 528,749 shares during the period. Institutional investors own 26.56% of the company's stock.
About CG Oncology
(
Get Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Featured Articles
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
